27-04-2006: Millipore Corporation and Serologicals Corporation announced that their boards of directors have approved a definitive agreement whereby Millipore will acquire Serologicals in an all cash transaction. The acquisition will transform Millipore into a company with combined annual revenues of approximately $1.4 billion, based on 2006 full year projections. Assuming stable foreign exchange rates, Millipore believes 2007 revenues for the combined company will grow between 9 and 11 percent over 2006 pro forma revenues.
According to the company, the strategic combination of Millipore and Serologicals will significantly strengthen Millipore's Bioscience Division by giving it leading positions in a broad range of high growth segments such as drug discovery products and services, antibodies, cell biology reagents, and stem cell research. Millipore expects to increase sales of Serologicals' products in international markets such as Europe, Asia and Japan, where Millipore has a significant presence. Millipore's Bioprocess Division will gain a cell culture supplements offering that will facilitate its entry into the $1 billion upstream bioprocessing market. As a result, Millipore will be the only company in the life science industry that can offer both upstream cell culture and downstream separation offerings for biopharmaceutical production, further strengthening its relationships with biotechnology and pharmaceutical customers.
The combined organization of approximately 5,800 employees will have significantly expanded R&D capabilities and a worldwide sales, sales support, and service organization of approximately 1,200 professionals selling a broad portfolio of complementary products.
This is where you can add this news to your personal favourites
Merck KGaA announced the successful completion of its acquisition of Millipore Corporation, a leading Life Science company based in Billerica, Massachusetts, USA, for an aggregate purchase price including debt and cash of approximately EUR 5.2 billion (US$ 7.0 billion). Merck agreed to acqu ... more
Merck KGaA and Millipore Corporation announced that they have entered into a definitive agreement under which Merck KGaA will acquire all outstanding shares of common stock of Millipore, for US$ 107 per share in cash, or a total transaction value, including net debt, of approximately € 5.3 ... more
Millipore Corporation announced the appointment of John Sweeney as Vice President of Millipore’s Life Science SBU. Most recently, Sweeney served as Vice President of Strategy and Marketing services for Millipore’s Bioscience Division.
Sweeney joined Millipore in 2003 as Director of Strateg ... more
Millipore is a multinational company with offices and subsidiaries in 47 countries and distributors and dealers in other countries. There are manufacturing sites and R&D sites around the world. With its global infrastructure, Millipore services multinational pharmaceutical and biotechnology ... more